Graviton Clears GV101 Phase II Entry in Friedreich’s Ataxia

Company: Graviton BioScience · Event Type: Clinical/Regulatory Signal · Product/Asset: GV101 · Subject: Friedreich’s Ataxia · Event Date: August 11, 2026 Summary Graviton BioScience said the FDA cleared an investigational new drug application for a capsule formulation of GV101, an oral selective ROCK2 inhibitor, enabling…